PFE · 8-K · 20260804PR000094

Acquisition / Partnership / Divestiture

PFIZER INC · 2026-08-04 · Importance 59 · Surprise 60 · In source text

Pfizer completed a strategic global licensing and collaboration agreement with Innovent Biologics on July 10, 2026, covering 12 early-stage and de novo cancer medicines. Innovent received a $650 million upfront payment and is eligible for up to $9.85 billion in development, regulatory and commercial milestones, plus up to double-digit royalties on approved product sales. The portfolio includes antibody-drug conjugates with differentiated payloads and multispecific antibodies with immune-engaging features. Pfizer and Innovent will share profits in the U.S., U.K. and European Union for four co-developed and co-commercialized programs.

Key facts

• Innovent Biologics received a $650 million upfront payment and is eligible for up to $9.85 billion in development, regulatory and commercial milestone payments and up to double-digit royalties on sales of each licensed product if approved; transaction closed July 10, 2026 source
• 2026 Adjusted diluted EPS guidance absorbs a $650 million Acquired In-Process R&D charge related to Innovent Biologics transaction that will be recorded in Q3 2026 with expected unfavorable impact of approximately $0.10 source
• Completed the Innovent Biologics, Inc. transaction on July 10, 2026 source
• Approximately $170 million invested in business development transactions during the first six months of 2026 source

Impact estimates